跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FLUENZ SUSPENSION PARA PULVERIZACION NASAL - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
FLUENZ SUSPENSION PARA PULVERIZACION NASAL
Approved
STANDARD
FLUENZ SUSPENSION PARA PULVERIZACION NASAL
Astrazeneca Ab
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jun 11, 2024
Approval ID
0ac761aab4fa0afc
Company
Astrazeneca Ab
Type
Standard
Approval Details
Approval Id
0ac761aab4fa0afc
Drug Cima Aemps Name
FLUENZ SUSPENSION PARA PULVERIZACION NASAL
Register Number
1241816001
Holder Company Name
Astrazeneca Ab
Marketing Company Name
Astrazeneca Farmaceutica Spain S.A.
Holder Company Detail Path
/organization/astrazeneca-ab
Authorization Date
2024-06-11
Dosage Form
SUSPENSIÓN PARA PULVERIZACIÓN NASAL
Dose
7 ± 0,5 log10
Route Of Administration
VÍA NASAL
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
Yes
Company Name
Astrazeneca Ab
Company Detail Path
/organization/astrazeneca-ab
Company Information
Pharmaceutical Company Name
ASTRAZENECA AB
Country Name
Spain
City Name
madrid,madrid,country_es
Address
CALLE RAIMUNDO FERNANDEZ VILLAVERDE 63
Website
http://www.astrazeneca.se
Active Ingredients
VIRUS INFLUENZA GRIPE, VIVO ATENUADO,REASORTANTE CEPA SIMILAR A A/ VICTORIA/4897/2022 (H1N1) PDM09
7,0 ± 0,5 FFU
VIRUS INFLUENZA GRIPE A/THAILAND/8/2022 (H3N2) IVR-237 CEPA SIMILAR A (A/THAILAND/8/2022)
7,0 ± 0,5 FFU
VIRUS INFLUENZA GRIPE REASORTANTE,VIVO, ATENUADO, CEPA SIMILAR A B/ AUSTRIA/1359417/2021
7,0 ± 0,5 FFU
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jun 11, 2024
Approval ID
0ac761aab4fa0afc
Type
Standard
Back to CIMA-AEMPS Approvals
